MedTrace Logo

Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.

NCT05831995 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-12-06

No results posted yet for this study

Summary

This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients with RAS or RAF or NF-1 mutated advanced solid tumors as ABM-168 may have a significant effect in inhibiting cell growth.

Conditions

  • Advanced Solid Tumor
  • RAS Mutation
  • RAF Mutation
  • NF1 Mutation

Interventions

DRUG

ABM-168

Dosage: 0.5 mg; 2 mg; 6 mg; once daily by oral administration

Sponsors & Collaborators

  • ABM Therapeutics Corporation

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-30
Primary Completion
2024-06-30
Completion
2024-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05831995 on ClinicalTrials.gov